Once-Yearly Reclast(R) Demonstrates Highly Significant Fracture Risk Reductions In The Treatment Of Postmenopausal Osteoporosis, New Study Shows

... New Phase III data presented forthe first time demonstrated that the investigational treatment Reclast(R)^(zoledronic acid) 5 mg was highly effective in reducing the incidence ofbone fracture in women with postmenopausal osteoporosis across the mostcommon fracture sites -- hip, spine and non-spine^^ -- with sustainedeffect over three years. [click link for full article] ...